Your browser doesn't support javascript.
loading
VYC-12 Injectable Gel Is Safe And Effective For Improvement Of Facial Skin Topography: A Prospective Study.
Niforos, François; Ogilvie, Patricia; Cavallini, Maurizio; Leys, Christophe; Chantrey, Jonquille; Safa, Marva; Abrams, Steve; Hopfinger, René; Marx, Ann.
Afiliação
  • Niforos F; Centre Chirurgical Niforos, Lyon, France.
  • Ogilvie P; SkinConcept, Munich, Germany.
  • Cavallini M; Unit of Plastic Surgery, CDI Hospital, Milan, Italy.
  • Leys C; Medical Skincare, Sint-Truiden, Belgium.
  • Chantrey J; ØNE aesthetic studiø, Cheshire, UK.
  • Safa M; La Jouvence, Neuchâtel, Switzerland.
  • Abrams S; Clinical Development, Allergan Plc, Irvine, CA, USA.
  • Hopfinger R; Clinical Development, Allergan Plc, Irvine, CA, USA.
  • Marx A; Clinical Development, Allergan Plc, Irvine, CA, USA.
Clin Cosmet Investig Dermatol ; 12: 791-798, 2019.
Article em En | MEDLINE | ID: mdl-31749628
ABSTRACT

OBJECTIVE:

Evaluate safety and effectiveness of VYC-12 (Juvéderm Volite; an injectable crosslinked hyaluronic acid gel designed to improve skin quality attributes such as surface smoothness and hydration) for facial intradermal injection. MATERIALS AND

METHODS:

In a prospective, single-arm study, subjects with moderate/severe cheek skin roughness per Allergan Skin Roughness Scale (ASRS) received VYC-12 in the cheeks and forehead, and/or neck, with touch-up treatment to correct asymmetry 30 days later and optional repeat treatment 9 months after last treatment. The primary effectiveness measure was ASRS responder rate (percentage of cheeks with ≥1-point improvement from baseline) at month 1. Skin hydration was instrument-assessed.

RESULTS:

Of 131 subjects treated, 31 (23.7%) received touch-up treatment. ASRS responder rate was 96.2% at month 1, 76.3% at month 4, 34.9% at month 6, and 87.1% after repeat treatment. Responder rate in cheeks with severe baseline roughness was 93.8%, 83.1%, and 52.3% at months 1, 4, and 6, respectively. Skin hydration improved significantly (P<0.01) from baseline at all timepoints through month 9. Injection site responses were as expected. All treatment-related adverse events were mild/moderate.

CONCLUSION:

VYC-12 safely and effectively improved skin smoothness up to 6 months and hydration lasting 9 months.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article